Table I.
Comparison of pre-treatment clinical characteristics of de novo AML patients who cleared DNMT3A R882 mutations at complete remission and of those who did not.
| Characteristic | Group 1* (n = 14) |
Group 2* (n = 42) |
P |
|---|---|---|---|
| Age, years | |||
| Median | 48 | 52 | 0·55 |
| Range | 28–65 | 28–72 | |
| Age group, n (%) | |||
| Younger (<60 years) | 11 (79) | 33 (79) | 1·00 |
| Older (≥60 years) | 3 (21) | 9 (21) | |
| Sex, n (%) | |||
| Male | 8 (57) | 25 (60) | 1·00 |
| Female | 6 (43) | 17 (40) | |
| Race, n (%) | |||
| White | 13 (93) | 39 (97) | 1·00 |
| Non-white | 1 (7) | 1 (3) | |
| Haemoglobin, g/l | |||
| Median | 83 | 94 | 0·06 |
| Range | 68–132 | 71–251 | |
| Platelet count, ×109/l | |||
| Median | 57 | 81 | 0·12 |
| Range | 13–266 | 16–347 | |
| WBC count, ×109/l | |||
| Median | 30–6 | 45–5 | 0·76 |
| Range | 5·3–131·7 | 2·0–248·0 | |
| Percentage of blood blasts | |||
| Median | 68 | 62 | 0·64 |
| Range | 6–97 | 0–96 | |
| Percentage of bone marrow blasts | |||
| Median | 69 | 75 | 0·86 |
| Range | 24–91 | 6–91 | |
| Extramedullary involvement, n (%) |
3 (25) | 16 (41) | 0·33 |
| Pretreatment cytogenetic findings, n (%) | |||
| Normal karyotype | 12 (86) | 36 (86) | 0·61 |
| Sole trisomy† | 1 (7) | 2 (5) | |
| Two numerical abnormalities‡ | 1 (7) | 0 (0) | |
| Sole deletion§ | 0 (0) | 3 (7) | |
| Complex karyotype with >5 abnormalities |
0 (0) | 1 (2) | |
| ELN Genetic Group¶ | |||
| Favourable | 7 (50) | 18 (46) | 1·00 |
| Intermediate-I | 7 (50) | 18 (46) | |
| Intermediate-II | 0 (0) | 2 (5) | |
| Adverse | 0 (0) | 1 (3) | |
| Transplantation in 1st CR, n (%) | |||
| Allogeneic | 2 (14) | 1 (2) | 0·06 |
| Autologous | 8 (57) | 17 (40) | |
| No transplantation | 4 (29) | 24 (57) | |
| Time from 1st CR to 1st CR sample (d) | |||
| Median | 0 | 0 | 0·17 |
| Range | 0–185 | 0–333 | |
| Time from 1st CR to 1st CR sample, n (%) | |||
| Same day | 10 (71) | 22 (52) | 0·10 |
| Within 1–7 d after CR date | 1 (7) | 3 (7) | |
| Within 7–30 d after CR date | 1 (7) | 0 (0) | |
| More than 30 d after CR date | 2 (14) | 17 (40) | |
| DNMT3A R882 VAF % at diagnosis | |||
| Median | 45 | 46 | 0·58 |
| Range | 40–50 | 41–50 | |
AML, acute myeloid leukaemia; CR, complete remission with remission sample obtained at any time point after morphological remission is achieved; ELN, European LeukaemiaNet; n, number; WBC, white blood cell; VAF, variant allele frequency.
Group 1 is defined as patients whose DNMT3A R882 mutation cleared below the VAF cut-off of 3% in their remission sample and who had no other AML mutation, and Group 2 is defined as patients with a DNMT3A R882 mutation with a VAF >3% with or without other AML mutations in their remission sample.
This category includes single patients with sole +4, +8, and +21, respectively.
The patient in this category had +Y and +8.
This category includes single patients with sole add(7)(q22), del(9) (q13q22) and del(20)(q12), respectively.